prikaz prve stranice dokumenta Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
  Download
PDF 1.14 MB
Scientific paper - Original scientific paper
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
Bone Marrow Transplantation, 59 (2024), 6; 803-812. https://doi.org/10.1038/s41409-024-02248-9
Passweg, Jakob R.; Baldomero, Helen; Ciceri, Fabio; de la Cámara, Rafael; Glass, Bertram; Greco, Raffaella; Hazenberg, Mette D.; Kalwak, Krzysztof; McLornan, Donal P.; Neven, Bénédicte; Perić, Zinaida; Risitano, Antonio M.; Ruggeri, Annalisa; Snowden, John A.; Sureda, Anna More authors...

Cite this document

Passweg, J. R., Baldomero, H., Ciceri, F., de la Cámara, R., Glass, B., Greco, R. ... Sureda, A. (2024). Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation, 59. (6), 803-812. doi: 10.1038/s41409-024-02248-9

Passweg, Jakob R., et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT." Bone Marrow Transplantation, vol. 59, no. 6, 2024, pp. 803-812. https://doi.org/10.1038/s41409-024-02248-9

Passweg, Jakob R., Helen Baldomero, Fabio Ciceri, Rafael de la Cámara, Bertram Glass, Raffaella Greco, Mette D. Hazenberg, et al. "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT." Bone Marrow Transplantation 59, no. 6 (2024): 803-812. https://doi.org/10.1038/s41409-024-02248-9

Passweg, J. R., et al. (2024) 'Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT', Bone Marrow Transplantation, 59(6), pp. 803-812. doi: 10.1038/s41409-024-02248-9

Passweg JR, Baldomero H, Ciceri F, de la Cámara R, Glass B, Greco R, and sur.. Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT. Bone Marrow Transplantation [Internet]. 2024 June [cited 2025 April 05];59(6):803-812. doi: 10.1038/s41409-024-02248-9

J. R. Passweg, et al., "Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT", Bone Marrow Transplantation, vol. 59, no. 6, pp. 803-812, June 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:286040. [Accessed: 05 April 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT
AuthorJakob R. Passweg
AuthorHelen Baldomero
AuthorFabio Ciceri
AuthorRafael de la Cámara
AuthorBertram Glass
AuthorRaffaella Greco
AuthorMette D. Hazenberg
AuthorKrzysztof Kalwak
AuthorDonal P. McLornan
AuthorBénédicte Neven
AuthorZinaida Perić
AuthorAntonio M. Risitano
AuthorAnnalisa Ruggeri
AuthorJohn A. Snowden
AuthorAnna Sureda
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 patients received advanced cellular therapies, 3205 of which were CAR-T. An additional 2854 patients received DLI. Changes compared to the previous year were an increase in CAR-T treatments (+27%) and decrease in allogeneic (−4.0%) and autologous HCT (−1.7%). Main indications for allogeneic HCT were myeloid malignancies (10,433; 58.4%), lymphoid malignancies (4,674; 26.2%) and non-malignant disorders (2572; 14.4%). Main indications for autologous HCT were lymphomas (7897; 32.9%), PCD (13,694; 57.1%) and solid tumors (1593; 6.6%). In allogeneic HCT, use of sibling donors decreased by −7.7%, haploidentical donors by −6.3% and unrelated donors by −0.9%. Overall cord blood HCT decreased by −16.0%. Use of allogeneic, and to a lesser degree autologous HCT, decreased for lymphoid malignancies likely reflecting availability of new treatment modalities, including small molecules, bispecific antibodies, and CAR-T cells. Pediatric HCT activity remains stable (+0.3%) with differences between allogeneic and autologous HCT. Use of CAR-T continues to increase and reached a cumulative total of 9039 patients treated with wide differences across European countries. After many years of continuous growth, increase in application of HCT seems to have slowed down.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleBone Marrow Transplantation
Numberingvol. 59, no. 6, pp. 803-812
p-ISSN0268-3369
e-ISSN1476-5365
DOIhttps://doi.org/10.1038/s41409-024-02248-9
URN:NBNurn:nbn:hr:105:286040
Publication2024-06
Document URLhttps://www.nature.com/articles/s41409-024-02248-9
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2024-11-11 09:34:16